John A. Abraham, MD, FACS, discusses future research efforts in tenosynovial giant cell tumor.
John A. Abraham, MD, FACS, founder, Orthopaedic Oncology Service, Rothman Orthopaedic Institute, and attending surgeon, Orthopaedic Surgery, Fox Chase Cancer Center, discusses future research efforts in tenosynovial giant cell tumor (TGCT).
Ongoing clinical trials are evaluating monoclonal antibodies and small molecule inhibitors as potential treatments for patients with TGCT, Abraham says.
Since the August 2019 approval of pexidartinib (Turalio) for patients with symptomatic TGCT, a benchmark in terms of systemic therapy has been established in this space, explains Abraham.
As such, investigational agents will have to demonstrate additional benefit compared with pexidartinib, which is associated with an overall response rate of approximately 38%.
Alternatively, as pexidartinib is associated with some toxicities, developing an agent with a lower toxicity profile would be beneficial for patients with TGCT, concludes Abraham.